Skip to main content

Table 2 Side effects of severe COVID-19 patients received hUC-MSCs

From: One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment

Patient number

Liver function

Urea

Cr

Blood routine

ECG

Tumor marker#

Thrombotic/embolic

Impaired vision

Analysis

ALT

AST

P1

25

37

4.96

60

Normal

Normal

Norma

Normal

Normal

 

P2

29

23

6.14

82

Normal

Normal

CA12-5 elevated*

Normal

Normal

Aged patient

P3

33

39

3.92

77

Normal

Normal

Normal

Normal

Normal

 

P4

15

18

3.44

57

Normal

Normal

Normal

Normal

Normal

 

P5

11

34

3.50

50

Normal

Normal

NSE elevated*

Normal

Normal

Slightly elevated

P6

15

10

3.14

55

Normal

Normal

Normal

Normal

Normal

 

P7

34

29

4.21

83

Normal

Normal

Normal

Normal

Normal

 

P8

20

26

5.11

61

Normal

Normal

Normal

Normal

Normal

 
  1. Normal range: ALT 9-50U/L; AST 15-40U/L; Urea 1.7–8.3 mmol/L; Cr 40–80 umol/L; CA12-5: 0–35 U/ml; NSE: 0–16.3 ng/ml
  2. ECG Electrocardiogram, ALT alanine aminotransferase, AST aspartate aminotransferase, Cr creatinine
  3. # Tumor marker includes: CEA, CA12-5, CA19-9, SCC, NSE, AFP, PSA (for males)
  4. *CA12-5: 53 U/ml; NSE:18.5 ng/ml